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Background: RAD51AP1 is a DNA-binding protein that
enhances RAD51 recombinase activity.
Results:Our analyses revealed that RAD51AP1 possesses
two DNA binding domains.
Conclusion: Both of the RAD51AP1 DNA binding
domains are needed for protein function.
Significance: The results shed light on the mechanism of
RAD51AP1 in the homology-directed repair of damaged
DNA.
Homologous recombination catalyzed by the RAD51 recombi-
nase is essential formaintaining genome integrity upon the induc-
tion of DNA double strand breaks and other DNA lesions. By
enhancing the recombinase activity of RAD51, RAD51AP1
(RAD51-associated protein 1) serves a key role in homologous
recombination-mediated chromosome damage repair. We show
here that RAD51AP1 harbors two distinct DNA binding domains
that arebothneeded formaximalprotein activity underphysiolog-
ical conditions. We have finely mapped the two DNA binding
domains in RAD51AP1 and generated mutant variants that are
impaired in either or both of theDNAbinding domains. Examina-
tion of these mutants reveals that both domains are indispensable
forRAD51AP1function incells.Theseandotherresults illuminate
the mechanistic basis of RAD51AP1 action in homologous DNA
repair.
Homologous recombination (HR)7 is a highly conserved
DNA repair mechanism that rids chromosomes of double
strand breaks and other deleterious lesions (1). As such, defects
in HR lead to genome instability and tumorigenesis (2–4). In
the HR reaction, the RAD51 recombinase polymerizes onto
ssDNA derived from the primary lesion to form a helical pro-
tein filament known as the presynaptic filament. The presynap-
tic filament searches for and invades a homologous dsDNA
donor, leading to the formation of a D-loop structure, which is
resolved by one of several pathways to generate different
recombinant types (5).
RAD51AP1 (RAD51-associated protein 1) interacts with
RAD51 (6) and colocalizes with RAD51 to double strand break
sites in cells (7). RAD51AP1knockdownbyRNAinterference ren-
ders cells hypersensitive to DNA-damaging agents, such as mito-
mycin C (MMC), and prone to chromatid breaks (8, 9).
RAD51AP1 binds DNA and stimulates the RAD51-mediated
D-loop reaction (8, 9). Based on biochemical studies, it has been
suggested that theDNAbinding activity in theC-terminal portion
of RAD51AP1 helps execute protein function (8). Surprisingly, as
reported herein, RAD51AP1 possesses a second, distinct DNA
binding domain that resides within the N-terminal portion of the
protein. Characterization of point mutants impaired for the two
DNA binding domains have provided evidence that both are
needed forDNAdamage resistanceof cells.These results arequite
unexpected and speak to the mechanism of action of RAD51AP1
in HR.
EXPERIMENTAL PROCEDURES
Plasmids—Plasmids for the Escherichia coli expression of the
full-length humanRAD51AP1 and the F1, F2, and F3 fragments
with N-terminal maltose-binding protein and C-terminal
(His)6 tags have been previously described (10). The C60 (resi-
dues 275–335) portion of RAD51AP1 was similarly cloned and
expressed. All point mutations, truncations, and fusions of
RAD51AP1were generatedwith a site-directedmutagenesis kit
(QuikChange XL, Stratagene) using the primers listed in sup-
plemental Table 1.
Purification of RAD51AP1 and Mutants—RAD51AP1 and
the F1, F2, and F3 fragments were purified using a procedure
that encompasses cation exchange and affinity chromato-
graphic steps, as described previously (10). The sameprocedure
was employed in the purification of various RAD51AP1-de-
rived polypeptides and mutants. RAD51 was expressed in
E. coli and purified as described previously (11).
DNA Substrates—The DNA substrates used in the DNA
binding and D-loop assays of this study have been described
previously (12).
DNA Mobility Shift Assay—This assay was conducted as
described previously (12).
Affinity Pulldown Assay—The indicated RAD51AP1 species
(5g) was incubated with RAD51 (5g) in 30l of buffer A (25
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mMTris-HCl, pH 7.5, 0.5 mM EDTA, 50 mM KCl) at 4 °C for 30
min. Then, 20 l of amylose resin (New England Biolabs) was
added followed by gentle mixing at 4 °C for 30min. After wash-
ing the resin, bound proteins were eluted with 20 l of 2% SDS.
The supernatant containing unbound proteins, wash, and the
SDS eluate, 10 l of each, was analyzed by 10% SDS-PAGE and
Coomassie Blue staining.
D-loop Assay—Unless stated otherwise, all the steps were
conducted at 37 °C. RAD51 (0.8 M) was incubated with radio-
labeled 90-mer Oligonucleotide (2.4 M nucleotides; refer to
Ref. 12 for sequence) in 9.5 l of buffer R (25 mM Tris-HCl, pH
7.5, 50 mM KCl, 1 mMMgCl2, 2 mM ATP, 1 mMDTT) for 5 min
to assemble the presynaptic filament. Then, the indicated
amount of RAD51AP1, RAD51AP1 polypeptide, or mutant
was incorporated in 2 l for 5 min, after which pBluescript
replicative form I DNA (35 M base pairs) was added in 1 l.
Following a 10-min incubation, reaction mixtures were
treated with 0.5% SDS and 0.5 mg/ml proteinase K for 20min
and then subjected to agarose gel electrophoresis in TAE
buffer (40 mM Tris, 20 mM NaOAc, pH 7.4, 2 mM EDTA) at
25 °C. Gels were dried and analyzed in a Personal Molecular
Imager FX (Bio-Rad), with quantification done using the
Quantity One software (Bio-Rad).
RAD51AP1 Expression Vectors, Transfection, and Selection of
Stable Cell Lines—The eGFP-RAD51AP1 expression vector
has been described (8). The eGFP-RAD51AP1res (resistant
to siRNA) expression vector was generated by site-directed
mutagenesis using the primer pair listed in supplemental Table
1. The N-K6RA or C-K7WA mutation8 was introduced as
described for the E. coli protein expression vectors above (see
“Results”). HeLa cells were transfected with the RAD51AP1res
expression vectors using Lipofectamine 2000 (Invitrogen) as
recommended by the manufacturer. Twenty-four hours after
transfection, cells were trypsinized, diluted in normal growth
medium containing 1.7 mg/ml G418, and plated in 96-well
plates at 30–1000 cells/well. Plates were re-fed with G418
twice, and colonies arising from single cells were picked 12 days
after transfection, expanded, and tested for expression of the
ectopic proteins by Western blot analysis using anti-GFP
(ab290, Abcam) and anti-RAD51AP1 antibody, as described
previously (13). Down-regulation of endogenous RAD51AP1 in
the stably transfected HeLa cell derivatives was mediated by
the RAD51AP1-directed siRNA with the sense sequence
CCUCAUAUCUCUAAUUGCAUU, as described previously
(8). In parental HeLa cells, RAD51AP1 was depleted using
RAD51AP1-directed siRNA with the sense sequence GCAG-
TGTAGCCAGTGATTA, as described previously (9).
MMC Cytotoxicity Test, Immunoprecipitation, and Western
Blot Analysis—To test forMMC sensitivity, a colony formation
assay was carried out using cell lines stably expressing wild type
or mutant eGFP-RAD51AP1res and in which endogenous
RAD51AP1 was depleted by siRNA, as described (8). Tran-
siently transfected HeLa cells were used for immunoprecipi-
tations. Briefly, 13 106 cells were seeded into 15-cm dishes
and, 20 h later, transfected with 70 g of RAD51AP1res plas-
mid and 35 g of HA-RAD51 plasmid (expressed from
pCMV-HA-RAD51) using Lipofectamine2000. Nuclear
extract was prepared 24 h after transfection, and immuno-
precipitation was carried out as described previously (9).
RESULTS
Two Distinct DNA Binding Domains in RAD51AP1—As
reported before (8) and confirmed here with a D-loop substrate
(supplemental Fig. 1, B and C), the C-terminal portion of
RAD51AP1 harboring residues 188–335 (F3 fragment; Fig. 1A
and supplemental Fig. 1A) binds DNA with a dissociation con-
stant of100nM.However, the analysis showed that full-length
RAD51AP1 (supplemental Fig. 1, B and C) has a higher affi-
nity (dissociation constant 40 nM) for the substrate. This
prompted us to address whether RAD51AP1may have another
DNA binding domain. Indeed, in another series of DNA bind-
ing experiments with a mixture of three substrates (ssDNA,
dsDNA, and D-loop), a RAD51AP1 fragment harboring the
N-terminal 94 residues (F1 fragment; Fig. 1A and supplemental
Fig. 1A) could bind DNA (Fig. 1, B and C). In contrast, the
middle portion of RAD51AP1 spanning residues 95–187 (F2
fragment; Fig. 1A and supplemental Fig. 1A) is clearly devoid of
DNA binding activity (Fig. 1B). Thus, RAD51AP1 possesses
two DNA binding domains residing within the N-terminal and
C-terminal regions of the protein, respectively.
Consistent with previously published results (8), the F3 frag-
ment could physically associatewith RAD51 (supplemental Fig.
1D) and could also enhance the RAD51-mediated D-loop reac-
tion (supplemental Fig. 1E). In contrast, neither F1 nor F2 could
bind RAD51 (supplemental Fig. 1D) nor stimulate D-loop for-
mation (supplemental Fig. 1E). Knowing that RAD51 interac-
tion is indispensable for the HR function of RAD51AP1 (8, 9),
we wondered whether endowing the F1 fragment with RAD51
binding activity would allow it to function in the D-loop reac-
tion. We therefore appended the C-terminal 60 residues of
RAD51AP1 that harbor the RAD51 binding domain (8, 9, 14)
but lack DNA binding activity (supplemental Fig. 2C) to the F1
fragment and purified the F1-C60 polypeptide to test in bio-
chemical systems (Fig. 2A and supplemental Fig. 2A). As
expected, the F1-C60 polypeptide bound DNA and RAD51
8 The multiple mutation designations used are: N-K6RA, K34A/K35A/
R37A/K41A/K44A/K47A/K49A C-K7WA, K231A/K232A/K234A/K236A/
K283A/K284A/K286A/W287A.
FIGURE 1. Two distinct DNA binding domains in RAD51AP1. A, the
RAD51AP1 fragments used in this study. FL, full-length RAD51AP1. B, purified
full-length RAD51AP1 or RAD51AP1 fragments (0.25, 0.9, and 2.0 M) were
tested for the ability tobind radiolabeledD-loop, dsDNA, and ssDNA.C, quan-
tification of results with error bars representing themean S.D. from at least
three independent experiments.
REPORT: DNA Binding by RAD51AP1 in DNA Repair
12344 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 287•NUMBER 15•APRIL 6, 2012









(supplemental Fig. 2, B and C) and, importantly, exerted a
strong stimulatory effect on D-loop formation to the level seen
with the F3 fragment (Fig. 2B). The results also showed thatC60
alone has no effect on D-loop formation (Fig. 2B). Thus, the
N-terminal DNA binding activity of RAD51AP1, when
endowed with a RAD51 interaction attribute, is functional in
the RAD51-mediated D-loop reaction.
Point Mutants Impaired for N-terminal DNA Binding
Domain—To define the minimal DNA binding domain in the
N-terminal region of RAD51AP1, we constructed and purified
protein fragments that harbor residues 1–29, 1–49, or 1–69
appended to the C60 fragment (29-C60, 49-C60, and 69-C60,
respectively) for biochemical testing (supplemental Fig. 3, A
and B). As expected, all three polypeptides interacted with
RAD51 (supplemental Fig. 3C). However, although 69-C60 and
49-C60 bound the DNA substrates as avidly as F1-C60 (com-
pare supplemental Fig. 3D and supplemental Fig. 2C), 29-C60
had a much lower affinity for the substrates (supplemental Fig.
3D). Consistent with these results, a deletion of the first 53
residues in F1-C60 (F153-C60; supplemental Fig. 3, A and B)
led to an impairment ofDNAbinding but had little or no effect on
RAD51 interaction (supplemental Fig. 3,C andD).When tested in
the D-loop assay, 69-C60 and 49-C60, but not 29-C60 or F153-
C60, enhanced product formation (supplemental Fig. 3E).
Altogether, the results above suggest that the region span-
ning residues 30 and 49 is important for DNA binding. This
RAD51AP1 region harbors several highly conserved basic resi-
dues, Lys-34, Lys-35, Arg-37, Lys-41, Lys-44, Lys-47, and Lys-
49, that could be involved in interaction with the negatively
charged phosphodiester backbone of the DNA ligand (supple-
mental Fig. 4A). To test this idea, we constructed two com-
pound mutants within the context of the F1-C60 polypeptide:
the K2RA mutant with the first 3 (Lys-34, Lys-35, and Arg-37)
basic residues changed to alanine, and the K6RA mutant with
all 7 basic residues changed to alanine (Fig. 3A). When these
two mutants, F1-K2RA-C60 and F1-K6RA-C60, were ex-
pressed in E. coli, they could be purified with similar yields as
the wild type counterpart (supplemental Fig. 5A). Biochemical
testing of these polypeptides revealed that although RAD51
interaction remains unaffected (supplemental Fig. 5B), both
mutants are attenuated for binding D-loop and dsDNA, with
the K6RA mutant exhibiting a more severe impairment (Fig.
3B). Importantly, we found that these mutants are largely
devoid of the ability to stimulate the D-loop reaction (Fig. 3C).
Point Mutants Impaired for C-terminal DNA Binding
Domain—According to the results of Modesti et al. (8), the
RAD51AP1 C-terminal DNA binding domain resides within
residues 226–290 of the protein. Sequence alignment of the
deduced DNA binding domain in RAD51AP1 orthologs
shows highly conserved basic and aromatic residues Lys-231,
Lys-232, Lys-234, Lys-236, Lys-283, Lys-284, Lys-286, and
Trp-287, that may be involved in ionic and stacking interac-
tions with the phosphodiester backbone and bases in the
DNA ligand, respectively (supplemental Fig. 4B). To test the
relevance of these residues in DNA binding and functionality
of RAD51AP1, we constructed and expressed three com-
pound point mutants within the context of the F3 frag-
ment, namely, K4A (K231A/K232A/K234A/K236A), K3WA
(K283A/K284A/K286A/W287A), and K7WA, in which sev-
eral or all (K7WA) of the aforementioned basic and hydro-
phobic residues have been changed to alanine (Fig. 3D).
These mutant polypeptides could be purified with a similar
yield as the wild type counterpart (supplemental Fig. 5C). In
biochemical testing, all three mutants were competent for
RAD51 interaction (supplemental Fig. 5D) but exhibited a
varying degree of DNA binding deficiency, with the K7WA
mutant being the most impaired in this regard (Fig. 3E).
Importantly, the three mutants were nearly or completely
devoid of stimulatory function in the D-loop reaction, in a
manner that paralleled their DNA binding defect (Fig. 3F).
The Two DNA Binding Domains Are Indispensable for Pro-
tein Function—To ask whether both DNA binding domains are
needed for RAD51AP1 function, we introduced the K6RA and
K7WA mutations that impair the N-terminal and C-terminal
DNA binding domains, singly (N-K6RA or C-K7WA) or in
combination (N-K6RA/C-K7WA), into full-length RAD51AP1
(Fig. 4A). Following expression, the mutant proteins could be
purified with a similar yield as the wild type counterpart
(supplemental Fig. 5E). As expected, the threemutants could all
associate with RAD51withwild type affinity (supplemental Fig.
5F). Results from DNA binding experiments showed that the
N-K6RA and C-K7WAmutants are both moderately impaired
for DNA binding (Fig. 4B), which is not surprising given that
each mutant still possesses a functional DNA binding domain.
Importantly, the N-K6RA/C-K7WA double mutant is strongly
impaired in this regard (Fig. 4B).
We next tested the proficiency of the three RAD51AP1
mutants in the D-loop reaction. Because the single mutants
possess a functional DNA binding domain, the D-loop reac-
tion was carried out under an increased level of KCl to the
FIGURE 2. Functionality of N-terminal DNA binding domain in D-loop reac-
tion. A, the F1-C60 polypeptide and C60 fragment used. B, the F1-C60 polypep-
tide and the F1, F3, and C60 fragments (0.5, 0.75, and 1 M) were tested with
RAD51 in theD-loop reaction. The resultswere quantified andplotted; error bars
aremean S.D. from at least three independent experiments.
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physiological level, i.e. 150 mM (versus 50 mM used in prior
experiments) to reveal any deficiency that may accompany
the DNA binding mutations. Under these conditions, either
single mutant is less adept at RAD51 enhancement, whereas
the double mutant is completely devoid of any RAD51 stim-
ulatory activity (Fig. 4C). Thus, both RAD51AP1 DNA bind-
ing domains are required for protein function.
Phenotypic Analysis of DNA Binding Mutants—RAD51AP1-
deficient cells are hypersensitive to genotoxic agents, such as
the DNA cross-linker MMC. Here, we examined the relevance
of the two DNA binding domains of RAD51AP1 in the repair
of MMC-induced damage. Based on the eGFP-RAD51AP1
expression vector described earlier (8), we designed eGFP-
RAD51AP1res mutants that harbor the N-K6RA or C-K7WA
mutation. We generated HeLa cell lines stably expressing wild
type or mutant eGFP-RAD51AP1res protein and selected
clones with comparable levels of ectopically expressed protein
(Fig. 4D). Although endogenous RAD51AP1 could be effi-
ciently knocked down by siRNA, all three eGFP-RAD51AP1res
variants were resistant to the treatment (Fig. 4D). Next, we
tested the ability of wild type ormutant eGFP-RAD51AP1res to
provide resistance to MMC-induced cell death upon depletion
of endogenous RAD51AP1 (Fig. 4E). Importantly, neither the
N-K6RA nor the C-K6WA mutant could protect cells from
MMC-induced death as well as the wild type protein (Fig. 4E).
By immunoprecipitation using anti-GFP antibody, we verified
FIGURE 3. Effects of mutations in the N- and C-terminal DNA binding domains. A, mutants of the F1-C60 polypeptide. B, the F1-C60 polypeptide and
mutants were tested for DNA binding, and the mean data  S.D. from at least three independent experiments are shown. C, the F1-C60 polypeptide and
mutants (0.5, 0.75, and 1M) were tested with RAD51 in the D-loop reaction. The results were quantified and plotted; error bars are mean S.D. from at least
three independent experiments.D, mutants of the F3 fragment. E, the F3 fragment andmutants were tested for DNA binding, and themean data S.D. from
at least three independent experiments are shown. F, the F3 fragment and mutants (0.5, 0.75, and 1 M) were tested with RAD51 in the D-loop reaction. The
results were quantified and plotted; error bars are mean S.D. from at least three independent experiments.
FIGURE 4. Requirement for the two DNA binding domains in RAD51AP1 function. A, mutants of full-length RAD51AP1 (FL). B, binding of the D-loop,
dsDNA, and ssDNA substrates by RAD51AP1 and mutants. Shown are the mean S.D. from at least three independent experiments. Note that the data
for wild type protein are from Fig. 1C. C, the full-length RAD51AP1 and mutants (0.5, 0.75, and 1 M) were tested with RAD51 in the D-loop reaction. The
results were quantified and plotted; error bars are mean  S.D. from at least three independent experiments. D, immunoblot analysis showing
attenuation of endogenous RAD51AP1 but not of each eGFP-RAD51AP1res by siRNA treatment.QM indicates the loading control.wt, wild type; neg. con.,
negative control. E, results from colony formation assays to assess the fraction of surviving cells after MMC treatment. F, immunoprecipitation and
Western blot analysis revealed that the wild type and eGFP-RAD51AP1res N-K6RA and C-K6WA mutants interact with both ectopically expressed
HA-RAD51 and endogenous RAD51, whereas eGFP alone cannot.
REPORT: DNA Binding by RAD51AP1 in DNA Repair
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that both RAD51AP1 mutants retain the ability to associate
with RAD51 (Fig. 4F). Taken together, our results suggested
that both the N-terminal and the C-terminal DNA binding
domains of RAD51AP1 are critical for its function in vivo.
Nonetheless, both theN-K6RA and theC-K7WADNAbinding
mutants appear to retain residual function because the expres-
sion of either mutant led to some protection from MMC-in-
duced cell death when compared with parental HeLa cells
depleted for endogenous RAD51AP1 (Fig. 4E). The retention of
partial function by the single mutants is likely because of the
presence of the other DNA binding domain endowing limited
function.
DISCUSSION
A previous study by Modesti et al. (8) has provided clear
evidence that the C-terminal region of RAD51AP1 possesses
a DNA binding activity. In fact, as shown before and as reit-
erated in this study, a C-terminal RAD51AP1 fragment har-
boring the reported DNA binding domain (8) and RAD51
interaction activity (8, 9, 14) can function in the D-loop reac-
tion. In this regard, our published studies have furnished
evidence that RAD51 interaction is critical for RAD51AP1
function, as point and deletion mutations that compromise
RAD51 interaction render RAD51AP1 ineffectual in the HR
reaction (9, 10). By alignment against orthologs, we have
identified residues that are conserved within the deduced
DNA binding domain, and several compound point muta-
tions of these residues weaken the DNA binding attribute of
the C-terminal RAD51AP1 fragment and its ability to stim-
ulate the RAD51-mediated D-loop reaction. Thus, our
efforts have helped pinpoint RAD51AP1 residues that are
important for the functionality of the C-terminal DNA bind-
ing domain.
Rather unexpectedly, we have found in this study a novel
DNA binding domain that resides within the N-terminal
region of RAD51AP1. Furthermore, we have shown that a
polypeptide consisting of this DNA binding domain fused to
the RAD51 interaction motif is capable of RAD51 enhance-
ment in the D-loop reaction. Via biochemical mapping and
sequence alignment of the deduced minimal domain against
the equivalent region in orthologs, conserved residues that
could be involved in DNA binding have been identified.
Indeed, two compound point mutations that alter these res-
idues compromise DNA binding activity and functionality of
this domain.
To address whether the two DNA binding domains are
redundant or act in concert in the promotion of RAD51AP1
function, we have introduced mutations that inactivate
either of the domains, singly or in combination, into the
full-length protein, purified the mutants, and tested them in
the D-loop reaction. Under conditions of physiological ionic
strength, the RAD51AP1 single and double mutants all
exhibit a functional defect that mirrors their DNA binding
deficiency. Importantly, by genetic complementation, we
have furnished evidence that the two DNA binding domains
are both required for full biological activity of RAD51AP1.
Recent studies have provided evidence for functional synergy
between RAD51AP1 and the tumor suppressor PALB2 in the
RAD51-mediated homologous DNA pairing reaction (13). We
note that PALB2 itself also possesses a DNA binding activity
(13). It will be of particular interest to test whether maximal
enhancement of RAD51 by the RAD51AP1-PALB2 pair
requires both the DNA binding domains of RAD51AP1 as well
as the DNA binding activity of PALB2.
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